Cargando…

Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors

BACKGROUND: Monocyte-derived-dendritic-cells (MDDC) are the major DC type used in vaccine-based clinical studies for a variety of cancers. In order to assess whether in vitro differentiated MDDC from cryopreserved PBMC of cancer patients are functionally distinct from those of healthy donors, we com...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghanekar, Smita A, Bhatia, Sonny, Ruitenberg, Joyce J, Rosa, Corazon DeLa, Disis, Mary L, Maino, Vernon C, Maecker, Holden T, Waters, Cory A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868730/
https://www.ncbi.nlm.nih.gov/pubmed/17477875
http://dx.doi.org/10.1186/1476-8518-5-7
_version_ 1782133392632971264
author Ghanekar, Smita A
Bhatia, Sonny
Ruitenberg, Joyce J
Rosa, Corazon DeLa
Disis, Mary L
Maino, Vernon C
Maecker, Holden T
Waters, Cory A
author_facet Ghanekar, Smita A
Bhatia, Sonny
Ruitenberg, Joyce J
Rosa, Corazon DeLa
Disis, Mary L
Maino, Vernon C
Maecker, Holden T
Waters, Cory A
author_sort Ghanekar, Smita A
collection PubMed
description BACKGROUND: Monocyte-derived-dendritic-cells (MDDC) are the major DC type used in vaccine-based clinical studies for a variety of cancers. In order to assess whether in vitro differentiated MDDC from cryopreserved PBMC of cancer patients are functionally distinct from those of healthy donors, we compared these cells for their expression of co-stimulatory and functional markers. In addition, the effect of cryopreservation of PBMC precursors on the quality of MDDC was also evaluated using samples from healthy donors. METHODS: Using flow cytometry, we compared normal donors and cancer patients MDDC grown in the presence of GM-CSF+IL-4 (immature MDDC), and GM-CSF+IL-4+TNFα+IL-1β+IL-6+PGE-2 (mature MDDC) for (a) surface phenotype such as CD209, CD83 and CD86, (b) intracellular functional markers such as IL-12 and cyclooxygenase-2 (COX-2), (c) ability to secrete IL-8 and IL-12, and (d) ability to stimulate allogeneic and antigen-specific autologous T cells. RESULTS: Cryopreservation of precursors did affect MDDC marker expression, however, only two markers, CD86 and COX-2, were significantly affected. Mature MDDC from healthy donors and cancer patients up-regulated the expression of CD83, CD86, frequencies of IL-12(+ )and COX-2(+ )cells, and secretion of IL-8; and down-regulated CD209 expression relative to their immature counterparts. Compared to healthy donors, mature MDDC generated from cancer patients were equivalent in the expression of nearly all the markers studied and importantly, were equivalent in their ability to stimulate allogeneic and antigen-specific T cells in vitro. CONCLUSION: Our data show that cryopreservation of DC precursors does not significantly affect the majority of the MDDC markers, although the trends are towards reduced expression of co-stimulatory makers and cytokines. In addition, monocytes from cryopreserved PBMC of cancer patients can be fully differentiated into mature DC with phenotype and function equivalent to those derived from healthy donors.
format Text
id pubmed-1868730
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18687302007-05-15 Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors Ghanekar, Smita A Bhatia, Sonny Ruitenberg, Joyce J Rosa, Corazon DeLa Disis, Mary L Maino, Vernon C Maecker, Holden T Waters, Cory A J Immune Based Ther Vaccines Original Research BACKGROUND: Monocyte-derived-dendritic-cells (MDDC) are the major DC type used in vaccine-based clinical studies for a variety of cancers. In order to assess whether in vitro differentiated MDDC from cryopreserved PBMC of cancer patients are functionally distinct from those of healthy donors, we compared these cells for their expression of co-stimulatory and functional markers. In addition, the effect of cryopreservation of PBMC precursors on the quality of MDDC was also evaluated using samples from healthy donors. METHODS: Using flow cytometry, we compared normal donors and cancer patients MDDC grown in the presence of GM-CSF+IL-4 (immature MDDC), and GM-CSF+IL-4+TNFα+IL-1β+IL-6+PGE-2 (mature MDDC) for (a) surface phenotype such as CD209, CD83 and CD86, (b) intracellular functional markers such as IL-12 and cyclooxygenase-2 (COX-2), (c) ability to secrete IL-8 and IL-12, and (d) ability to stimulate allogeneic and antigen-specific autologous T cells. RESULTS: Cryopreservation of precursors did affect MDDC marker expression, however, only two markers, CD86 and COX-2, were significantly affected. Mature MDDC from healthy donors and cancer patients up-regulated the expression of CD83, CD86, frequencies of IL-12(+ )and COX-2(+ )cells, and secretion of IL-8; and down-regulated CD209 expression relative to their immature counterparts. Compared to healthy donors, mature MDDC generated from cancer patients were equivalent in the expression of nearly all the markers studied and importantly, were equivalent in their ability to stimulate allogeneic and antigen-specific T cells in vitro. CONCLUSION: Our data show that cryopreservation of DC precursors does not significantly affect the majority of the MDDC markers, although the trends are towards reduced expression of co-stimulatory makers and cytokines. In addition, monocytes from cryopreserved PBMC of cancer patients can be fully differentiated into mature DC with phenotype and function equivalent to those derived from healthy donors. BioMed Central 2007-05-03 /pmc/articles/PMC1868730/ /pubmed/17477875 http://dx.doi.org/10.1186/1476-8518-5-7 Text en Copyright © 2007 Ghanekar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Ghanekar, Smita A
Bhatia, Sonny
Ruitenberg, Joyce J
Rosa, Corazon DeLa
Disis, Mary L
Maino, Vernon C
Maecker, Holden T
Waters, Cory A
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
title Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
title_full Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
title_fullStr Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
title_full_unstemmed Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
title_short Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
title_sort phenotype and in vitro function of mature mddc generated from cryopreserved pbmc of cancer patients are equivalent to those from healthy donors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868730/
https://www.ncbi.nlm.nih.gov/pubmed/17477875
http://dx.doi.org/10.1186/1476-8518-5-7
work_keys_str_mv AT ghanekarsmitaa phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT bhatiasonny phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT ruitenbergjoycej phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT rosacorazondela phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT disismaryl phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT mainovernonc phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT maeckerholdent phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors
AT waterscorya phenotypeandinvitrofunctionofmaturemddcgeneratedfromcryopreservedpbmcofcancerpatientsareequivalenttothosefromhealthydonors